Clinical Trials Logo

Systemic Sclerosis clinical trials

View clinical trials related to Systemic Sclerosis.

Filter by:

NCT ID: NCT00962923 Recruiting - Systemic Sclerosis Clinical Trials

Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc)

Start date: August 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This study will explore safety and efficacy of allogeneic mesenchymal stem cells transplantation (MSCT) to treat patients with diagnosis of systemic sclerosis(SSc) who have been resistant to multiple standard treatments. The underlying hypothesis is that the SSc condition is caused by an abnormal immune homeostasis that can be restored by MSCT.

NCT ID: NCT00573326 Recruiting - Systemic Sclerosis Clinical Trials

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Start date: February 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to verify effect and tolerability of imatinib on pulmonary and skin fibrosis in patients affected by systemic sclerosis.

NCT ID: NCT00453752 Recruiting - Systemic Sclerosis Clinical Trials

Non-Invasive Diagnostic and Functional Evaluation of Cardiac Involvement in Patients With Systemic Sclerosis

Start date: April 2006
Phase: N/A
Study type: Observational

The aim of this study was to assess serum N-terminal proBNP (NT-proBNP) in systemic sclerosis patients and to establish whether it reflects the severity of RV overload.

NCT ID: NCT00006393 Recruiting - Systemic Sclerosis Clinical Trials

Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis

Start date: July 1998
Phase: N/A
Study type: Observational

OBJECTIVES: I. Determine whether defects in fibrillin-1 cellular processing are present in the tsk1 mouse model that carries a known FBN1 gene rearrangement and in a population of Choctaw Native American patients with systemic sclerosis who have a strong genetic predisposition to the disease. II. Determine the ultrastructural features of fibrillin-1 in these patients. III. Screen the FBN1 gene for mutations beginning at the regions homologous to the tsk1 duplication and latent transforming growth factor binding proteins in these patients and in an unaffected Choctaw control group. IV. Determine the correlation between fibrillin-1 abnormalities and clinical presentation, autoantibodies, and ethnicity.